tremelimumab-actl injection,
for intravenous use Initial U.S. Approval: 2022

As specified in the prescribing information, tremelimumab-actl injection is indicated for the treatment of unresectable hepatocellular carcinoma (uHCC) and non-small cell lung cancer (NSCLC).  IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Facts about tremelimumab-actl injection

Approval Date: 10/21/2022
Proprietary Name: Imjudo
Active Ingredient(s): tremelimumab-actl
FDA-approved use: To treat unresectable hepatocellular carcinoma
Dosage Form:
Injection: 25 mg/1.25 mL (20 mg/mL) solution in a single-dose vial.
Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “tremelimumab-actl injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.